Steve Stavs on Muck Rack

Steve Stavs

Johannesburg
As seen in: The Made to Thrive Show, Bizcommunity, HT Syndication
Speaker. Global Podcaster. 11x Comrades Finisher. I help high achievers boost their energy levels, performance and health. DM me to book a consult.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Steve

Contact Steve, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Dementia care takes a leap forward with new photo reminiscence therapy research Original

|
By Steve Stavs, Kenneth McLeod, Ruth Itzhaki
| Bizcommunity Verified
Advertise your job vacancies 2 days7 days30 daysBy Industry Show more The need for affordable, drug-free technology to help the growing elderly population and their caregivers advanced in August as leaders in Photo Reminiscence Therapy (pRT), including NIDE, CERTUS Institute, and Vivid-Pix, started their second research project in Colorado, Florida, and Wisconsin.
Open in Who Shared View Duplicates (4) Issue with article?

Growth contracts as consumers recalibrate - Clur Shopping Centre Index

|
By Steve Stavs, Katja Hamilton, Anna Ringstrom Verified, Rishika Sadam Verified
| Bizcommunity Verified
Growth in trading density levels at more than 4 million square metres of prime retail space in South Africa contracted further in 2023, dipping below the annual inflation rate, according to the Clur Shopping Centre Index. Source: Supplied. Belinda Clur, managing director of Clur International.
Open in Who Shared View Duplicates (6) Issue with article?

Research on Alzheimer drug reveals new cell health mechanism Original

|
By Matthew Hirsch, Steve Stavs, Katja Hamilton
| Bizcommunity Verified
Advertise your job vacancies Memantine is one of the main drugs prescribed for patients with mild to severe Alzheimer’s disease. Yet, despite an 8.5% increase worldwide in the use of the drug between 2008 and 2018, uncertainties remain regarding the most favourable treatment concentrations. To address this question, scientists in the Department of Physiological Sciences at Stellenbosch University (SU) investigated the concentration-dependent effect of memantine in a neuronal cell model.
Open in Who Shared View Duplicates (4) Issue with article?
See all 9 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified